登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600252 证券简称：中恒集团 公告编号：临2026-8 广西梧州中恒集团股份有限公司 关于控股孙公司纳米炭铁混悬注射液联合放疗II期 临床试验获得伦理批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，广西梧州中恒集团股份有限公司（以下简称"公司"或"中恒集团"）控股子公司重庆莱美药业股份 有限公司（以下简称"莱美药业"）之子公司四川瀛瑞医药科技有限公司（以下简称"瀛瑞医药"）自主研 发的"纳米炭铁混悬注射液"（以下简称"纳米炭铁"）于近期在四川大学华西医院顺利通过了伦理审查并 收到了临床试验伦理审查委员会的正式批件，标志着纳米炭铁联合放疗正式进入II期临床试验阶段。现 将相关情况公告如下： 一、纳米炭铁临床试验进展情况 目前，纳米炭铁的I期临床试验已顺利完成，主要评估不同剂量的纳米炭铁单药单次给药在晚期实体瘤 患者中的安全性、耐受性、药代动力学特征和初步疗效。纳米炭铁IbIIa期临床试验已完成部分受试者入 组，疗效随访中，主要评估不同剂量的纳米炭铁 ...

Core Viewpoint - Zhongheng Group's subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its innovative anti-cancer drug, "Nano Carbon Iron Suspension Injection" [1][2] Group 1: Product Development - The drug "Nano Carbon Iron" is a next-generation nano drug developed based on Laimei's existing product, utilizing Fe2+ as the active anti-cancer ingredient and nano carbon as its carrier [1] - The mechanism of action involves regulating ferroptosis pathways to exert anti-cancer effects, with the drug administered via intratumoral injection to inhibit tumor growth [1] Group 2: Clinical Trial and Mechanism - The approved clinical trial will explore the safety and potential efficacy of the combination of "Nano Carbon Iron" and standard radiotherapy in treating solid tumors [2] - Research indicates that the mechanisms of action of "Nano Carbon Iron" and radiotherapy are complementary, potentially enhancing the local treatment effects, especially in large, hypoxic tumors that are difficult to control with radiotherapy alone [2]